Skip to main content

Arrowhead Releases HBV White Paper

Premium

Arrowhead Research this week released a white paper detailing the market potential for a hepatitis B therapy and the use of its dynamic polyconjugate siRNA-delivery technology to attack the virus.

The white paper can be found here.

"The development of a ... HBV candidate began under Roche and we are very pleased with the progress that our scientists have made," David Lewis, vice president of biology at Arrowhead, said in a statement.

He added that additional information about Arrowhead's HBV program, which was announced last month (GSN 2/16/2012), will be made public at upcoming scientific conferences and in peer-reviewed papers.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.